These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 24812045

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 4. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.
    Mult Scler; 2016 Jul 29; 22(8):1048-60. PubMed ID: 26432858
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH, Moraes L, Fink MC, Callegaro D, Romano CM, Oliveira AC.
    Arq Neuropsiquiatr; 2014 Dec 29; 72(12):960-5. PubMed ID: 25465776
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C, Montalban X.
    CNS Drugs; 2014 Jul 29; 28(7):641-8. PubMed ID: 24942634
    [Abstract] [Full Text] [Related]

  • 9. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC.
    Mult Scler; 2014 May 29; 20(6):757-60. PubMed ID: 24189572
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 12. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F, Newsome SD, Viscidi R.
    Mol Cell Probes; 2015 Feb 29; 29(1):54-62. PubMed ID: 25483260
    [Abstract] [Full Text] [Related]

  • 13. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov 29; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 14. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 15; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 16. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun 15; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 17. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.
    PLoS Pathog; 2012 Jun 15; 8(11):e1003014. PubMed ID: 23144619
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K, Gold R.
    Nat Rev Neurol; 2017 Dec 15; 13(12):710-712. PubMed ID: 29146954
    [No Abstract] [Full Text] [Related]

  • 20. Advances in the management of PML: focus on natalizumab.
    Fox R.
    Cleve Clin J Med; 2011 Nov 15; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.